|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment of gastric cancer显示文摘The authors focused on the current surgical treatment of resectable gastric cancer,and significance of periand post-operative chemo or chemoradiation.Gastric cancer is the 4thmost commonly diagnosed cancer and the second leading cause of cancer death worldwide.Surgery remains the only curative therapy,while perioperative and adjuvant chemotherapy,as well as chemoradiation,can improve outcome of resectable gastric cancer with extended lymph node dissection.More than half of radically resected gastric cancer patients relapse locally or with distant metastases,or receive the diagnosis of gastric cancer when tumor is disseminated;therefore,median survival rarely exceeds12 mo,and 5-years survival is less than 10%.Cisplatin and fluoropyrimidine-based chemotherapy,with addition of trastuzumab in human epidermal growth factor receptor 2 positive patients,is the widely used treatment in stageⅣpatients fit for chemotherapy.Recent evidence supports the use of second-line chemotherapy after progression in patients with good performance | Michele Orditura Gennaro Galizia Vincenzo Sforza Valentina Gambardella Alessio Fabozzi Maria Maddalena Laterza Francesca Andreozzi Jole Ventriglia Beatrice Savastano Andrea Mabilia Eva Lieto Fortunato Ciardiello Ferdinando De Vita | 2014 | World Journal of Gastroenterology2014，20，7： | 116 |
| 2 | Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients显示文摘AIM: To evaluate vascular endothelial growth factor(VEGF) and tryptase in hepatocellular cancer(HCC)before and after trans-arterial chemoembolization(TACE).METHODS: VEGF and tryptase serum concentrations were assessed from 71 unresectable HCC patients before and after hepatic TACE performed by binding DC-Beads?to doxorubicin. VEGF levels were examined for each serum sample using the Quantikine Human VEGF-enzyme-linked immuno-absorbent assay(ELISA),whereas tryptase serum concentrations were assessed for each serum sample by means of fluoro-enzyme immunoassay(FEIA) using the Uni-CAP100 tool.Differences between serum VEGF and tryptase values before and after TACE were evaluated using Student t test. Person's correlation was used to assess the degree of association between the two variables.RESULTS: VEGF levels and serum tryptase in HCCpatients before TACE had a mean value and standard deviation(SD) of 114.31 ± 79.58 pg/mL and 8.13± 3.61 μg/L, respectively. The mean levels and SD of VEGF levels and serum tryptase in HCC patients after TACE were 238.14 ± 109.41 pg/mL and 4.02 ±3.03 μg/L. The changes between the mean values of concentration of VEGF and tryptase before treatment and after treatment was statistically significant(P <0.000231 and P < 0.00124, by Wilcoxon-Mann-Whitney respectively). A significant correlation between VEGF levels before and after TACE and between tryptase levels before and after TACE was demonstrated(r =0.68, P = 0.003; r = 0.84, P = 0.000 respectively).CONCLUSION: Our pilot results suggest that the higher serum VEGF levels and the lower tryptase levels following TACE may be potential biomarkers changing in response to therapy. | Girolamo Ranieri Michele Ammendola Ilaria Marech Annamaria Laterza Ines Abbate Caroline Oakley Angelo Vacca Rosario Sacco Cosmo Damiano Gadaleta | 2015 | World Journal of Gastroenterology2015，21，19： | 13 |
| 3 | Clinical management of advanced gastric cancer: The role of new molecular drugs显示文摘Gastric cancer is the fourth most common malignant neoplasm and the second leading cause of death for cancer in Western countries with more than 20000 new cases yearly diagnosed in the United States.Surgery represents the main approach for this disease but,notwithstanding the advances in surgical techniques,we observed a minimal improvement in terms of overall survival with a significant increasing of relapsing disease rates.Despite the development of new drugs has significantly improved the effectiveness of chemothera-py,the prognosis of patients with unresectable or metastatic gastric adenocarcinoma remains poor.Recently,several molecular target agents have been investigated;in particular,trastuzumab represents the first target molecule showing improvements in overall survival in human epithelial growth factor 2-positive gastric cancer patients.New molecules targeting vascular epithelial growth factor,mammalian target of rapamycin,and anti hepatocyte growth factor-c-Met pathway are also under investigation,with interesting results.Anyway,it seems necessary to select more accurately the population to treat with new agents by the identification of new biomarkers in order to optimize the results.In this paper we review the actual'scenario'of targeted treatments,also focusing on the new agents in development for gastric cancer and gastro-esophageal carcinoma,discussing their efficacy and potential applications in clinical practice. | Ferdinando De Vita Natale Di Martino Alessio Fabozzi Maria Maddalena Laterza Jole Ventriglia Beatrice Savastano Angelica Petrillo Valentina Gambardella Vincenzo Sforza Luigi Marano Annamaria Auricchio Gennaro Galizia Fortunato Ciardiello Michele Orditura | 2014 | World Journal of Gastroenterology2014，20，40： | 12 |
| 4 | Pathophysiology and biology of peritoneal carcinomatosis显示文摘Peritoneal carcinomatosis represents a devastating form of cancer progression with a very poor prognosis.Its complex pathogenesis is represented by a dynamic process comprising several steps.To the best of our knowledge pathogenesis can be partly explained by 3 major molecular pathways: (1) dissemination from the primary tumor;(2) primary tumor of peritoneum;and (3) independent origins of the primary tumor and peritoneal implants.These are not mutually exclusive and combinations of different mechanisms could occur inside a single case.There are still several aspects which need explanation by future studies.A comprehensive understanding of molecular events involved in peritoneal carcinomatosis is of paramount importance and should be systematically pursued not only to identify novel strategies for the prevention of the condition,but also to obtain therapeutic advances,through the identification of surrogate markers of prognosis and development of future molecular targeted therapies. | Shigeki Kusamura Dario Baratti Nadia Zaffaroni Raffaella Villa Barbara Laterza Maria Rosaria Balestra Marcello Deraco | 2010 | World Journal of Gastrointestinal Oncology2010，2，1： | 8 |
| 5 | Diagnosis and management of gastric antral vascular ectasia显示文摘Gastric antral vascular ectasia (GAVE) is an uncommon but often severe cause of upper gastrointestinal (GI) bleeding, responsible of about 4% of non-variceal upper GI haemorrhage. The diagnosis is mainly based on endoscopic pattern and, for uncertain cases, on histology. GAVE is characterized by a pathognomonic endoscopic pattern, mainly represented by red spots either organized in stripes radially departing from pylorus, defined as watermelon stomach, or arranged in a diffused-way, the so called honeycomb stomach. The histological pattern, although not pathognomonic, is characterized by four alterations:vascular ectasia of mucosal capillaries, focal thrombosis, spindle cell proliferation and fibrohyalinosis, which consist of homogeneous substance around the ectatic capillaries of the lamina propria. The main differential diagnosis is with Portal Hypertensive Gastropathy, that can frequently co-exists, since about 30% of patients with GAVE co-present a liver cirrhosis. Autoimmune disorders, mainly represented by Reynaud's phenomenon and sclerodactyly, are co-present in about 60% of patients with GAVE; other autoimmune and connective tissue disorders are occasionally reported such as Sjogren's syndrome, systemic lupus erythematosus, primary biliary cirrhosis and systemic sclerosis. In the remaining cases, GAVE syndrome has been described in patients with chronic renal failure, bone marrow transplantation and cardiac diseases. The pathogenesis of GAVE is still obscure and many hypotheses have been proposed such as mechanical stress, humoural and autoimmune factors and hemodynamic alterations. In the last two decades, many therapeutic options have been proposed including surgical, endoscopic and medical choices. Medical therapy has not clearly shown satisfactory results and surgery should only be considered for refractory severe cases, since this approach has significant mortality and morbidity risks, especially in the setting of portal hypertension and liver cirrhosis. Endoscopic therapy, particularly treatment with Argon Plasma Coagulation, has shown to be as effective and also safer than surgery, and should be considered the first-line treatment for patients with GAVE-related bleeding. | Lorenzo Fuccio Alessandro Mussetto Liboria Laterza Leonardo Henry Eusebi Franco Bazzoli | 2013 | World Journal of Gastrointestinal Endoscopy2013，5，1： | 8 |
| 6 | The role of K- ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-analysis of prospective studies显示文摘 | Lorenzo Fuccio Cesare Hassan Liboria Laterza Loredana Correale Nico Pagano Paolo Bocus Carlo Fabbri Antonella Maimone Vincenzo Cennamo Alessandro Repici Guido Costamagna Franco Bazzoli Alberto Larghi | 2013 | Gastrointestinal Endoscopy2013，，： | 4 |
| 7 | Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy显示文摘Peritoneal surface malignancies have been traditionally regarded as end-stage conditions amenable to merely palliative options. The combination of aggressive cytoreductive surgery (CRS), involving peritonectomy procedures and multivisceral resections, with intra-operative hyperthermic intra-peritoneal chemotherapy (HIPEC) and/or early postoperative intra-peritoneal chemotherapy (EPIC) to treat the microscopic residual tumor is a new concept. In recent years, promising results have been reported for peritoneal mesothelioma and carcinomatosis of gastrointestinal and gynaecologic origin treated by this combined protocol. However, CRS with HIPEC and/or EPIC is a complex procedure associated with high rates of potentially life-threatening complications. Furthermore, disease progression following comprehensive treatment is not uncommon and represents a relevant cause of treatment failure. The present paper reviews the available information on early postoperative management and long-term follow-up in patients treated with CRS and intraperitoneal chemotherapy. The peculiar clinical and biological alterations that can be expected during an uncomplicated postoperative course, as compared to standard digestive surgery, are discussed. Early recognition and appropriate management of the most common adverse events are addressed, in order to minimize the impact of treatment-related morbidity on survival and quality of life results. Since re-operative surgery with additional HIPEC, has proven to be useful in selected patients with recurrent disease, long-term surveillance aiming at early detection of postoperative disease progression has become a relevant issue. Current results on follow-up investigations are presented. | Dario Baratti Shigeki Kusamura Barbara Laterza Maria Rosaria Balestra Marcello Deraco | 2010 | World Journal of Gastrointestinal Oncology2010，2，1： | 4 |
| 8 | Can early precut implementation reduce endoscopic retrograde cholangiopancreatography-related complication risk? Meta-analysis of randomized controlled trials显示文摘 | V. Cennamo L. Fuccio R. Zagari L. Eusebi L. Ceroni L. Laterza C. Fabbri F. Bazzoli | 2010 | Endoscopy2010，，05： | 3 |
| 9 | Gastric metastasis from ovarian adenocarcinoma presenting as a subepithelial tumor and diagnosed by endoscopic ultrasound-guided tissue acquisition显示文摘We describe an uncommon case of a patient with a metastatic adenocarcinoma of ovarian origin presented as a gastric subepithelial tumor(SET) and that was diagnosed by endoscopic ultrasound fine-needle biopsy(EUS-FNB). Malignant gastric lesions are rarely metastatic and the primary tumor is mainly breast, lung, esophageal cancer or cutaneous melanoma. Gastric metastasis from ovarian cancer is unusual, presenting synchronously with the primary tumor but also several years later than the initial diagnosis. From an endoscopic point of view, gastric metastasis does not present specific features. They may mimic both a primary gastric tumor or, less frequently, an SET.This case demonstrates the importance of EUS-FNB in distinguishing SETs and how this may alter treatment and prognosis. | Filippo Antonini Liboria Laterza Lorenzo Fuccio Massimo Marcellini Lucia Angelelli Sonia Calcina Corrado Rubini Giampiero Macarri | 2017 | World Journal of Gastrointestinal Oncology2017，9，11： | 3 |
| 10 | Experience with peritoneal mesothelioma at the Milan National Cancer Institute显示文摘Diffuse malignant peritoneal mesothelioma (DMPM) is an uncommon and rapidly fatal tumor.Therapeutic options have traditionally been limited and ineffective.The biologic and molecular events correlated with poor responsiveness to therapy are still poorly understood.In recent years,an innovative treatment approach involving aggressive cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy has reportedly resulted in improved outcome,as compared to historical controls.Since 1995,at the National Cancer Institute (NCI) of Milan (Italy),patients with DMPM have been treated with CRS and hyperthermic intraperitoneal chemotherapy (HIPEC).In the present paper,clinical experiences and basic science investigations on DMPM at Milan NCI are reviewed.Perioperative and long-term outcome results with CRS and HIPEC are presented.Clinico-pathological prognostic factors were investigated by multivariate analysis.The pathologic features and immunohistochemical markers related to DMPM biologic behavior were assessed in a large case-series uniformly treated at our institution.The prevalence and prognostic role of telomere maintenance mechanisms,which account for the limitless cell replicative potential of many malignancies,were studied.The dysregulation of the apoptotic pathways may play a role in the relative chemo-resistance of DMPM and a better understanding of apoptosis-related mechanisms could result in novel targeted therapeutic strategies.On this basis,the expression of survivin and other IAP family members (IAP-1,IAP-2,and X-IAP),the pro-apoptotic protein Smac/DIABLO,and antigens associated with cell proliferation (Ki-67) and apoptosis (caspase-cleaved cytokeratin-18) were analyzed.Finally,analyses of EGFR,PDGFRA and PDGFRB were performed to ascertain if deregulation of RTK could offer useful alternative therapeutic targets. | Marcello Deraco Dario Baratti Antonello Domenico Cabras Nadia Zaffaroni Federica Perrone Raffaella Villa Jenny Jocollè Maria Rosaria Balestra Shigeki Kusamura Barbara Laterza Silvana Pilotti | 2010 | World Journal of Gastrointestinal Oncology2010，2，2： | 3 |
| 11 | Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome?显示文摘AIM To evaluate the prevalence of nodular lymphoid hyperplasia(NLH) in adult patients undergoing colonoscopy and its association with known diseases. METHODS We selected all cases showing NLH at colonoscopy in a three-year timeframe, and stratified them into symptomatic patients with irritable bowel syndrome(IBS)-type symptoms or suspected inflammatory bowel disease(IBD), and asymptomatic individuals undergoing endoscopy for colorectal cancer screening.Data collection included medical history and final diagnosis. As controls, we considered all colonoscopies performed for the aforementioned indications during the same period.RESULTS One thousand and one hundred fifty colonoscopies were selected. NLH was rare in asymptomatic individuals(only 3%), while it was significantly more prevalent in symptomatic cases(32%). Among organic conditions associated with NLH, the most frequent was IBD, followed by infections and diverticular disease. Interestingly, 31% of IBS patients presented diffuse colonic NLH. NLH cases shared some distinctive clinical features among IBS patients: they were younger, more often female, and had a higher frequency of abdominal pain, bloating, diarrhoea, unspecific inflammation, self-reported lactose intolerance and metal contact dermatitis. CONCLUSION About 1/3 of patients with IBS-type symptoms or suspected IBD presented diffuse colonic NLH, which could be a marker of low-grade inflammation in a conspicuous subset of IBS patients. | Anna Chiara Piscaglia Lucrezia Laterza Valentina Cesario Viviana Gerardi Rosario Landi Loris Riccardo Lopetuso Giovanni Calò Giovanna Fabbretti Massimo Brisigotti Maria Loredana Stefanelli Antonio Gasbarrini | 2016 | World Journal of Gastroenterology2016，22，46： | 2 |
| 12 | Primary Carcinoma of the hypopharynx and cervical esophagus: evolution of surgical therapy显示文摘 | Laterza E MosciaroO UrsoUS | 1994 | Hepatogastroenterology1994，41，3： | 2 |
| 13 | Diffuse Malignant Peritoneal Mesothelioma: Failure Analysis Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)显示文摘 | D. Baratti MD S. Kusamura MD PhD A. D. Cabras MD P. Dileo MD B. Laterza MD M. Deraco MD | 2009 | Annals of Surgical Oncology2009，，2： | 2 |
| 14 | Gut Microbial Flora, Prebiotics, and Probiotics in IBD: Their Current Usage and Utility显示文摘 | Franco Scaldaferri Viviana Gerardi Loris Riccardo Lopetuso Fabio Del Zompo Francesca Mangiola Ivo Bo?koski Giovanni Bruno Valentina Petito Lucrezia Laterza Giovanni Cammarota Eleonora Gaetani Alessandro Sgambato Antonio Gasbarrini Michael Mahler | 2013 | BioMed Research International2013，，： | 2 |
| 15 | Prognostic Value of Circulating Tumor Markers in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy显示文摘 | Dario Baratti MD Shigeki Kusamura MD PhD Antonia Martinetti MD Ettore Seregni MD Barbara Laterza MD Daniela G. Oliva MD Marcello Deraco MD | 2007 | Annals of Surgical Oncology2007，，8： | 2 |
| 16 | Cytoreductive surgery and hyper- thermic intraperitoneal chemotherapy (H1PEC) in the treatment of pseu- domyxoma peritonei: ten years experi- ence in a single center 显示文摘 | Deraco M Kusamura S Laterza B et a | 2006 | In Vivo2006，20，6： | 1 |
| 17 | A comparison of urinary complications following total laparoscopic radical hysterectomy and laparoscopic pelvic lymphadenectomy to open abdominal surgery显示文摘 | Ueeella S Laterza R Ciravolo G | 2007 | Gynecol Oncol2007，107，11： | 1 |
| 18 | Cystatin C:an improved estimator of glomerular filtration rate 显示文摘 | Laterza OF Price CP Scott MG | 2002 | Clin Chem2002，48，5： | 1 |
| 19 | Impact of mode of delivery on levator morphology: a prospective observational study with three - dimensional ultrasound early in the postpartum period显示文摘 | ALBRICH S B LATERZA R M SKALA C | 2012 | BJOG - An International Journal of Obstetrics and Gynaecology2012，119，1： | 1 |
| 20 | Eosinophilic esophagitis is a component of the anticonvulsant hypersensitivity syndrome: Description of two cases显示文摘 | C. Balatsinou A. Milano M.P. Caldarella F. Laterza S.D. Pierdomenico F. Cuccurullo M. Neri | 2007 | Digestive and Liver Disease2007，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员